Clinuvel Pharmaceuticals (ASX:CUV) reported Thursday that its earnings per diluted share in the fiscal first half rose to AU$0.28 from AU$0.212 a year earlier.

Analysts polled by Visible Alpha were expecting an EPS of AU$0.20.

Revenue for the six months ended Dec. 31, 2024, was AU$35.6 million, up from AU$32.3 million in the same period a year earlier. Analysts surveyed by Visible Alpha expected AU$35.6 million.

The company's shares rose past 8% in recent Thursday trade.